1. Home
  2. KREF vs ZNTL Comparison

KREF vs ZNTL Comparison

Compare KREF & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

N/A

Current Price

$5.40

Market Cap

337.4M

Sector

Real Estate

ML Signal

N/A

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$1.73

Market Cap

289.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KREF
ZNTL
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.4M
289.0M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
KREF
ZNTL
Price
$5.40
$1.73
Analyst Decision
Hold
Strong Buy
Analyst Count
6
11
Target Price
$7.00
★ $7.44
AVG Volume (30 Days)
924.6K
★ 1.4M
Earning Date
10-28-2026
11-09-2026
Dividend Yield
★ 7.46%
N/A
EPS Growth
N/A
★ 18.03
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$349.17
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.94
$1.28
52 Week High
$9.11
$6.95

Technical Indicators

Market Signals
Indicator
KREF
ZNTL
Relative Strength Index (RSI) 41.39 33.46
Support Level $5.09 $1.63
Resistance Level $6.01 $2.76
Average True Range (ATR) 0.34 0.17
MACD 0.02 0.02
Stochastic Oscillator 42.60 19.47

Price Performance

Historical Comparison
KREF
ZNTL

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: